{"id":484075,"date":"2021-04-29T07:06:31","date_gmt":"2021-04-29T11:06:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/blueprint-medicines-reports-first-quarter-2021-financial-results\/"},"modified":"2021-04-29T07:06:31","modified_gmt":"2021-04-29T11:06:31","slug":"blueprint-medicines-reports-first-quarter-2021-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/blueprint-medicines-reports-first-quarter-2021-financial-results\/","title":{"rendered":"Blueprint Medicines Reports First Quarter 2021 Financial Results"},"content":{"rendered":"
\n

— 7 research- and clinical-stage programs highlighted at AACR, including recently nominated development candidate with best-in-class potential targeting CDK2 —<\/h2>\n

— GAVRETO\u00ae (pralsetinib) becomes the first selective RET inhibitor approved in China; AYVAKIT\u2122\/AYVAKYT\u00ae (avapritinib) becomes the first precision therapy for patients with PDGFRA exon 18 mutant GIST in China —<\/h2>\n

— Preparing to launch avapritinib in advanced SM in Q2 2021 —<\/h2>\n

— On track to initiate Phase 1 trial of BLU-945 in EGFR-driven NSCLC in Q2 2021 and Phase 2\/3 HARBOR trial of BLU-263 in non-advanced SM in mid-2021 —<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n CAMBRIDGE, Mass.<\/span>, April 29, 2021<\/span> \/PRNewswire\/ —\u00a0Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2021<\/span>.<\/p>\n

\n

\n
\n \"Print\"
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“In recent months, we made significant progress toward achieving our key 2021 portfolio goals, illustrating our clinical leadership in systemic mastocytosis and the rapid advancement of our next wave of therapeutic candidates with first- or best-in-class potential,” said Jeff Albers<\/span>, Chief Executive Officer of Blueprint Medicines. “With a potential U.S. approval for AYVAKIT in advanced systemic mastocytosis in the second quarter, we are looking forward to welcoming a new era of precision medicines care for people living with this debilitating disease. In parallel, we are initiating multiple clinical trials across our pipeline, beginning with the Phase 1 trial of BLU-945 and Phase 2\/3 HARBOR trial of BLU-263, as we continue to translate our research productivity and precision therapy expertise to address patient need across cancers and hematologic malignancies. Taken together, these accomplishments position Blueprint Medicines to help an increasing number of patients globally as we advance our robust portfolio.”<\/p>\n

\n First Quarter 2021 Highlights and Recent Progress<\/b>\n <\/p>\n

\n AYVAKIT\u2122\/AYVAKYT\u00ae (avapritinib): systemic mastocytosis (SM)<\/b>\n <\/p>\n